INTRODUCTION
Mucopolysaccharidosis type I (MPSI) is a metabolic-inherited disorder due to the deficit of the housekeeping lysosomal enzyme a-L-iduronidase (IDUA; EC 3.2.1.76), involved in the degradation of the glycosaminoglycans (GAG) heparan and dermatan-sulfate. Clinical symptoms and pathological features of the disorder, including heart disease, corneal clouding, organomegaly, skeletal malformations and joint stiffness, are due to the progressive accumulation of undegraded GAG in the cell lysosomes. 1 At least three different forms are recognized, from the most severe, Hurler syndrome (OMIM # 607014), also characterized by a heavy neurological involvement, to the intermediate and less severe forms, Hurler/Scheie (OMIM # 607015) and Scheie (OMIM #607 016), characterized by less severe neurological signs. 2 To date, two main therapeutic approaches have been successfully applied to the disease, haematopoietic stem cell transplantation and, more recently, enzyme replacement therapy (ERT), although they both present several limitations. [3] [4] [5] [6] Haematopoietic stem cell transplantation needs to be performed only once in life if engraftment is successful and it can preserve cognitive functions in MPSI patients; however, it necessitates the finding of histocompatible donors, its efficacy strictly relies on the early age of the patient, 4, 7 especially if efficacy on the brain compartment is required, as in severe patients, and the procedure still presents a significant risk of morbidity and mortality and of primary and secondary graft failure. 4 ERT, 5, 6 consisting of weekly intravenous administration of the recombinant enzyme, has so far shown encouraging results with an improvement of most of the organ systems involved, although no positive effects were described for heart, bones and brain, this last due to the inability of the enzyme to cross the blood brain barrier. Other important limitations include the need of weekly administration and the elevated costs of intervention. 8 The potential use of other therapeutic strategies, possibly ameliorating patients' compliance and lifestyle, and in the meantime determining a reduction of the costs, is highly desirable. New therapeutic strategies could be proposed as alternatives or in association with the existing ones, in combined protocols. Few clinical trials were proposed in the late 1990s for the gene therapy of the disorder. All of them proposed retroviruses as delivery vectors, although none of them has reached phase III to date (data obtained from the Wiley Database on Gene Therapy Clinical Trials Worldwide). More promising may be the latest preclinical gene therapy studies proposed using lentivirus or adeno-associated viral vectors. 9 In the present study, we tested the therapeutic efficacy of a somatic cell therapy approach based on the intra-peritoneal implantation of microcapsules enclosing C2C12 myoblasts engineered to overexpress IDUA.
Alginate-poly-L-lysine-alginate microcapsules are considered very biocompatible and the material has low immunogenicity. Structures enclose allogeneic cells able to produce clinically relevant amounts of the desired protein. 10 Encapsulated cells can survive for months and release the recombinant product constitutively starting at 24 h after injection. 11 Thus, microcapsules could be proposed for the treatment of MPSI as well as other lysosomal storage disorders to overcome some of the limitations described above. In particular, they could reduce both the frequency of hospitalization and the costs. Most importantly, they could provide a continuous delivery of the enzyme compared with the bolus delivery provided by the weekly administration.
Alginate-poly-L-lysine-alginate microcapsules have been used in the design of therapeutic strategies for various medical conditions. 12 In 2003 Barsoum et al. 13 reported the implantation of MPSI dogs in the brain (intra-ventricular) with alginate microcapsules enclosing Madin Darby canine kidney cells secreting canine a-iduronidase. However, the study was unsuccessful due to the important immune response developed. Therefore, despite the fact that various routes of administration have been explored, most of the applications are designed to implant encapsulated cells intra-peritoneally, where a single injection can be effective for several months. This presents multiple advantages for systemic supply and distribution of therapeutics.
As for other MPSs, intra-peritoneal implantation of microcapsules has been successfully applied to the preclinical treatment of MPSVII and MPSII mouse models. 11, 14 The present paper reports the results obtained following administration of IDUA-releasing microcapsules into the peritoneum of the knockout mouse model for MPSI (IDUA-ko), 15 and evaluates systemic therapeutic effects over a 4-months follow-up period.
RESULTS
In vitro evaluation of engineered myoblasts IDUA expression. In all, 95 different cell clones were isolated, about 70% of which revealed to be PCR-positive for the idua gene. On average, analysis of IDUA activity in the cell clones was detected about 10-fold higher than that measured in healthy primary fibroblasts and about 500-fold higher than C2C12 myoblasts baseline. Among the 60 idua-positive clones analyzed, the one showing the highest activity (4700 nmol mg À1 of protein per h) was expanded and subsequently used for enclosure in alginate-poly-L-lysine-alginate microcapsules.
Analysis of cell survival inside capsules
The implanted batch of capsules showed a cell viability around 90%. Cell viability, measured along with the entire follow-up on capsules retrieved from the animal peritoneum, showed a progressive decrease and reached at 16 weeks after implantation a value of about 35% (data not shown).
IDUA activity measured in the same batch just before implantation detected a value around 220 nmol 17 h À1 ml À1 of microcapsules. The same evaluation, performed on microcapsules recovered from the animals at different time points along with the follow-up, showed a total maintenance of the activity up to 8 weeks after implantation followed by the loss of 54 and 65% of the activity at 12 and 16 weeks after implantation, respectively ( Figure 1 ).
In vivo experiments
Experimental plan. In all, 12 IDUA-ko mice plus 4 heterozygote controls were implanted with 8.6Â10e6 viable cells per mouse contained in a total volume of 4 ml of capsules. As just before implantation cells expressed an IDUA activity around 220 nmol 17 h À1 ml À1 of microcapsules, by using a standard curve, performed with serial dilutions of the purified enzyme, we calculated that implanted capsules allowed a continuous release of 26.4 mg of enzyme, a dosage of 1.056 mg kg À1 for a 25 g mouse.
Mice follow-up was performed by analyzing blood and urine samples from pretreatment to 16 weeks after implantation. In particular, blood withdrawal was performed every 1-3 weeks, and on the plasma samples obtained both induced IDUA activity and antibody titer were evaluated. Urine samples were collected every 2-4 weeks. IDUA activity induced by the treatment in the tissues as well as GAG deposits were evaluated following mice sacrifice at 4, 8, 12 and 16 weeks after implantation.
Plasma IDUA activity. Figure 2 shows IDUA activity detected in the IDUA-ko mice plasma. Basal level was undetectable. Starting at 2 weeks after implantation an induced activity was observed in the animals, reaching at 12 weeks the mean level detected in the untreated heterozygote mice (14 nmol 17 h À1 ml À1 ). In the following weeks a progressive decrease of the induced activity was measured in the treated animal model. Anti-IDUA immune response. Figure 3 shows the follow-up of the immune response to the recombinant protein, induced by the treatment. Determinations were conducted with the enzyme-linked immunosorbent assay procedure as described in the Materials and Methods section. An increasing antibody titer was progressively detected in the IDUA-ko mice and at lower extent in the heterozygotes' group. An immunoprecipitation assay was also performed to determine the neutralizing effect of the antibodies on the IDUA activity (not extensively reported) showing that an antibody titer with an optical density value around 0.15 could neutralize about 50% of the enzyme activity expressed by the 50 ng of IDUA used for the assay. In our experiments, a mean 50% reduction and more of the enzyme activity was measured starting at 13 weeks after implantation only in the knock-out animals. A slight, progressive increase of the antibody titer was detected in the heterozygous treated mice.
Tissue IDUA activity. Induced enzyme activity was measured in the tissues of the euthanized mice at 4, 8, 12 and 16 weeks treatment while no activity was ever detected in the untreated animals. Results, reported in Figure 4 , although registering variability both among the organs and, in some cases, inter-individually, clearly evidenced an important acquired IDUA activity due to the treatment at all time points. In particular, in the heart levels were consistently X7% of the baseline activity detected in healthy wild-type controls, reaching values of 20% at 16w of treatment. A consistent induced activity was also detected in the kidney (on average 5-8% of the wild-type mean level) and in the liver (on average 3-33%). A lower induction was measured in the spleen, around 2% compared with wild-type levels.
Urinary glycosaminoglycan levels. Urinary GAG monitoring ( Figure 5 ) detected up to 8-weeks treatment a progressive reduction of the levels in the treated IDUA-ko animals (48% decrement), and remained significantly reduced up to 10-weeks follow-up (40% decrement). A progressive increase of urinary GAGs was measured in the following weeks, when we also registered an important inter-animal variability.
Biochemical evaluation of tissue glycosaminoglycan content and histochemical analysis. Tissue GAG content was measured in liver, kidney, spleen and heart at the four time points ( Figure 6 ). A reduction of GAG deposits was observed in all tissues, more evident at 8 weeks and statistically significant for liver and spleen. Animals euthanized in the following weeks, up to the end of the follow-up, showed lower GAG reductions, although on average GAG maintained below the baseline level in liver and heart; however, at 16 weeks in kidney and spleen we detected values higher and equal to untreated ones, respectively.
Notably, along the follow-up we measured in the liver (Figure 6a ) a 64 and a 78% decrease at 4 and 8 weeks, respectively (P¼0.036 e P¼0.023), and in the spleen ( Figure 6c ) the GAG decrement was 68% at 8 weeks (P¼0.018). In the kidney (Figure 6b ) at the same time point a 43% reduction was measured, and in the heart (Figure 6d ) we registered a mean GAG decrease between 28 and 55% along the follow-up. Table 1 reports all the data obtained from the single animals, given as percentage of decrease with respect to the mean GAG values measured in the IDUA-ko untreated mice. An important decrease was detected in the liver at all time points, except in one animal, while for the other organs considered, but for the spleen at 8 weeks of treatment, an important inter-individual variability was observed. Overall, 25 organs out of the 48 analyzed showed a GAG decrement of at least 40% (bold), 10 organs showed a decrease of GAG content between 7.5 and 38.6%, and 6 organs did not show any Figure 3 Follow-up of the immune response to the recombinant protein, induced by the treatment in IDUA-ko and heterozygote mice. Determinations were conducted in plasma samples using the enzyme-linked immunosorbent assay. Horizontal doted line represents the optical density value, measured at 405 nm, corresponding to a neutralizing effect on IDUA activity equal to 50%. Each point represents the mean ± s.e.m.; for IDUA-ko mice n¼12 at 0 (basal level),1, 2 weeks; n¼9 at 6, 7 weeks; n¼6 at 9, 11 weeks; n¼3 at 13, 16 weeks. For heterozygote mice n¼4 at all time points. Somatic cell therapy in MPSI E Piller Puicher et al difference when compared with untreated mice values (nc). Finally, in 7 organs out of 48 we measured a GAG content higher than the mean value detected in the untreated group of animals (up), from 8.9 to 94.6%. The 'cured' IDUA-ko mice. Two of the treated IDUA-ko mice, sacrificed at 8 and 12 weeks after implantation, respectively, showed at the end of the follow-up a complete depletion of the tissue glycosaminoglycan deposits, up to normalization. In addition, both animals showed a significant recombinant IDUA activity in the plasma (average value for the entire follow-up: 12.6 and 17.7 nmol 17 h À1 ml À1 ) and in the liver (at sacrifice: 47.8 and 4.1 nmol 17 h À1 mg À1 ). Figure 8 shows the most important results obtained on the parameters evaluated. Analysis of tissue GAG deposits by using the biochemical assay revealed a general decrease of the storage. By taking into account liver, spleen, heart and kidney we detected an average 0.00 and 0.07 mg of GAG per mg of protein. Urinary GAG levels showed a significant decrease along the follow-up with a mean reduction around 40% with respect to start levels (Figure 8a ). Detailed results, related to urinary GAG, plasma IDUA activity induced by the treatment and titer of anti-IDUA antibodies at several time points are reported in Figures 8b, c and d . These data were confirmed by the histochemical examination ( Figure 9 ) where tissues derived from the treated mouse are shown in panel b. GAG deposits appeared generally reduced, particularly in liver and kidney. In the liver we could also observe a correction of hepatic cell vacuolization. In the spleen a reduction of GAGs was observed in the connective tissue of the parenchyma and in the capsule. In the heart, together with a reduction of GAG deposits, a remarkable improvement of the tissue architecture was observed. 
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DISCUSSION
The availability of the recombinant enzyme allowing the set up of the enzyme replacement therapeutic strategy (ERT) has undoubtedly changed clinical conditions and lifestyle of MPSI patients, 5, 6 although it could not achieve the same efficacy in all treated subjects. 6 In addition, it presents limitations which are partly common to ERT protocols adopted for other lysosomal storage disorders, such as the inability to help the neurological involvement affecting most MPSI patients, and the necessary weekly hospitalization required by the infusion protocols, which reduces patients' compliance. The necessity to evaluate alternative enzyme administration protocols, aimed at reducing patient hospitalization and therefore improving the treatment's compliance, has induced us to evaluate the therapeutic efficacy and the safety of the approach described in this work. In addition, the implantation of engineered allogeneic cells overexpressing the enzyme lacking in the disorder, as proposed in this study, although unable to address the neurological impairment, should allow a continuous release of the correcting enzyme and also an important reduction of the present costs of treatment. This study follows a previous experience performed by our group in the mouse model for MPSII (Hunter syndrome) in which alginatepoly-L-lysine-alginate microcapsules were intra-peritoneally implanted and safety/efficacy monitoring was performed up to 8 weeks after implantation. 14 That study clearly showed that the efficacy of the strategy on different peripheral organ systems could be appreciated even after a few weeks of treatment. In the present work, performed in the MPSI mouse model, a similar procedure was adopted to assess safety and efficacy during a medium-term follow-up (up to 16 weeks implantation), where analysis was progressively performed at several time points. Compared with the previous experiments, in this study mice were implanted with a higher amount of viable cells (about 8Â10e6 cells per animal) due to the higher viability of the cells inside capsules. Implanted cells maintained such high viability and ability to produce active enzyme for several weeks along the experiment, as shown by the evaluations performed on microcapsules retrieved from the animal peritoneum at sacrifice: a decrease of IDUA activity was first noticed 12 weeks after implantation. Up to that time, implanted capsules could produce the human recombinant enzyme and release it into the animal blood. In parallel, search of plasma anti-IDUA antibodies showed that the protein is more immunogenic in IDUA-ko than heterozygous mice, perhaps the good similarity between the human and the murine IDUA (77% protein sequence identity, BLAST software by NCBI, www.ncbi.nlm.nih.gov/BLAST/) allows a slower immune reaction in the heterozygous mice, which are not naïve to IDUA. The key role of encapsulated cells to elicit an immune response against the recombinant protein produced was previously shown. 16 In particular, C2C12 myoblasts seem to be particularly prone to arising an immune response in the implanted mice. Although in the near future it would be interesting to perform experiments similar to the ones proposed in this study by using a different cell line, as the G8, 16 the present work was undertaken based on our previous experience with MPSII. 14 In that work no immune response against the recombinant IDS was detected in the implanted mice, either immunosuppressed or not, up to 8 weeks after treatment. In the present work immune reaction against recombinant IDUA was detected starting at 4 weeks after implantation, but plasmatic IDUA activity induced by the treatment could be detected up to the end of the follow-up. The immune reaction was somehow expected as IDUA immunogenicity is known from the clinical experience in the patients, 5, 6 although it does not seem to correlate with infusionassociated reaction or reduction of GAGs. 6 The main objective of both studies was for us to ascertain the feasibility of the proposed therapeutic approach in the animal models, for a period of time sufficient to allow the possible efficacy of the treatment on GAG deposits. Plasma antibody levels as well as enzyme activity induced by the treatment were constantly monitored in the alive mice, while efficacy was partly monitored by urinary GAG levels. Nevertheless, an evaluation of other encapsulated cells, as primary human cells, will 
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have to be undertaken, although possible immune reaction against human cells could be expected in mice. Also, analysis of repeated implantation of capsules in the same mice will have to be conducted. The volume of capsules implanted in our mice allowed a release of enzyme around 1 mg kg À1 , a dosage higher than that recommended for the patients in ERT (0.58 mg kg À1 ). However, a real comparison of the two procedures would be quite difficult, due to the diverse pharmacokinetics of the two approaches. In fact, microcapsule implantation permits a continuous release of IDUA, likely allowing a constant plasmatic and tissue level of enzyme, whereas ERT foresees a bolus delivery provided by a weekly administration. The real amount of protein reaching the different organs systems is also difficult to clearly define. Once produced, the enzyme quickly reaches the bloodstream and in turn the organ systems where it is rapidly used to correct the pathological deposits. Therefore, in our experience induced enzyme activity can only be detected in the tissues following a continuous administration of enzyme, as we obtained in this work. What really provides information on the appropriateness of the approach is the therapeutic efficacy of the procedure, by evaluating in our case possible correction of GAG deposits and amelioration of the histopathological findings.
An acquired IDUA activity was already detectable in all the organs examined at 4 weeks after implantation, in a significant amount in the liver and in lower amounts in the other organs. In all, except for the heart, maximum induced enzyme activity was measured at 8 weeks follow-up; specifically in the liver, analysis of mice sacrificed at the subsequent time points detected a much lower IDUA activity, with a very low discrepancy among the animals examined. The lowest induced activities were measured in the spleen, in which IDUA was maintained for the entire follow-up at levels of 1-2% with respect to the level detected on average on healthy untreated control mice. According to the literature, even the lowest induced enzymatic level (1-2%) reached by the present treatment might be sufficient to obtain a correction of the pathological phenotype. 17, 18 Indeed, our evaluation of the efficacy of the procedure on the biochemical reduction of GAG deposits has shown that also low enzyme levels could significantly reduce mucopolysaccharides accumulation in the spleen. In the liver, in which higher induced activity was detected, a more significant Figure 9 Histochemical analysis of GAG storage in the 'cured' mice. Representative sections of the liver, kidney, spleen and heart obtained from untreated IDUA-ko (a), treated IDUA-ko (animal 57, 8 weeks treatment) (b), wild-type control (c) mice. Sections (5 mm) were stained with 1% alcian blue, counterstained with 0.1% nuclear fast red. Original magnification Â100 in all sections reported. Black arrows indicate GAG deposits or tissue alterations associated to the pathological phenotype. Scale bar corresponds to 40 mm.
Somatic cell therapy in MPSI E Piller Puicher et al reduction could be observed. In kidney and heart, the reduction observed in the deposits was not significant. Kidney represents the main excretory way for GAGs, which, in the urine, are significantly higher in this animal model compared with wild-type mouse, starting at few weeks of life. Therefore, it is possible that the progressive GAG elimination by the tissues through the blood would cause a temporary accumulation of partially degraded GAGs in the kidney, and mainly in the cortical glomerules. As for the heart, the relatively low effect measured in this organ as GAG decrease in most of the treated mice, might be related to the general inefficacy of the recombinant IDUA enzyme on mitral valve, recently described in a Hurler patient and also to the refractory behavior to treatment reported for the mouse model aorta by Herati and colleagues. 19, 20 Brain intake of rhIDUA was not evaluated in the present paper as well as brain GAG correction due to the treatment, given the known inability of the enzyme to cross the blood-brain barrier. Data available from http://www.fda.gov/ on preclinical pharmacology studies carried on by Biomarin Pharmaceutical Inc. on Aldurazyme (Novato, CA, USA), the ERT for the treatment of MPSI patients, cite experiments performed in animal models for MPSI, including dogs and cats. All studies, including a 74-week intravenous infusion, declare no positive findings on the animal brain following administration of the drug, both as a bolus or continuously. As a consequence of these studies, the drug was proposed to treat the non-central nervous system manifestations of the disease. Also, an evaluation of the effect of the approach in this study proposed on bones and joints, which are importantly involved in the disease, remains an important question to address with future experiments which, however, should be performed in much younger animals. In fact, at the time of implantation these mice were adult, therefore no major skeletal correction could be expected from the treatment. Unfortunately, even haematopoietic stem cell transplantation performed in MPSI patients around 10 years of age, could not register bone correction. 7 What was really encouraging in the present experiments was the detection of a complete normalization of the deposits in two of the treated animals, of which one was sacrificed at 8 weeks and the second one at 12 weeks follow-up. In fact, no biochemical deposits were detected in all tissues of both mice. Such finding was confirmed by histochemical analysis.
A GAG level decrease, approaching normal, was previously described in the cat model of the disease following intravenous administration of the recombinant IDUA, at a dosage of 0.58 mg kg À1 , performed once a week for 3 months. 21 This paper, however, evidenced that although still viable and releasing some active enzyme, microencapsulated cells can determine an important curative effect mainly in the first weeks after implantation, reasonably not longer than 12 weeks. After that, we measured a significant decrease of IDUA activity produced by the capsules retrieved from the animals, up to 65% compared with the initial activity measured. Therefore, it is possible that the amount of enzyme produced might result insufficient to maintain its therapeutic efficacy. This could be correlated to a progressive decrease of the cell's viability inside capsules. Such decrease of efficacy was also evidenced by the analysis of urinary GAG levels showing a significant decrease up to 10 weeks after implantation and afterward slightly increasing up to basal level in about 6 weeks. Therefore, this paper shows that the use of engineered cells incorporated in microcapsules could obtain an important therapeutic effect on MPSI, although it suggests that the treatment should be repeated on average every 3 months. Other questions remain open and need to be solved before the clinical application of the technique, as the scaling up of the procedure to human beings, which could be obtained only by increasing the number of cells contained in the capsules, thus reducing the total volume to be injected in the peritoneum, and the availability of GMP facilities for a controlled production of microcapsule batches suitable for human treatment. We believe that our paper represents an important proof of concept that administration of an adequate amount of engineered cells protected by biocompatible capsules could provide an useful endogenous source of recombinant IDUA enzyme able to restore a normal phenotype. However, as our positive findings were found on a small number of animals, extrapolation to human benefit must be done with cautious optimism. Based on our present findings, a further experiment with a large cohort of younger animals could be performed, also addressing specific points as possible efficacy on joints and bones.
Somatic cell therapy approaches have been more extensively considered in the last years both in Europe and in North America, where legislations have been set up to provide useful indicators to address production and clinical applications in this field. 22, 23 More specifically, the increasing number of studies applying the use of bioencapsulation which has characterized the last decade, has evidenced an important need of technical guidelines useful for an efficient and safety use of microcapsules and, above all, for a possible translation of the technology to clinical practice. 24 
MATERIALS AND METHODS

Cells and cell clones
C2C12 murine myoblasts (CRL-1772, ATCC, Manassas, VA, USA) were grown in complete Dulbecco's modified Eagle's medium and 10% fetal bovine serum (Gibco-Invitrogen, Milano, Italy). Cells were kept in incubator at 37 1C, humidified atmosphere and 5% CO 2 . Human IDUA complementary DNA had been cloned in an expression cassette containing the human cytomegalovirus promoter and the bovine growth hormone polyA + intron B. 25 Cell clones were obtained by transfecting the cells with a ratio DNA/Lipofectamine 2000 (Gibco-Invitrogen) 1:1 w/v. G418 selection was performed at 800 mg ml À1 (Sigma-Aldrich, Milano, Italy). Selected cells were afterward analyzed for recombinant protein production by using a fluorometric assay (see section). The cell clone expressing the highest amount of IDUA was encapsulated.
Cell encapsulation
Cells were encapsulated in alginate as previously described: cells were mixed with the polymer and extruded through a syringe needle aided by airflow. 26 The resulting droplets were ionically cross-linked with Ca 2+ to form a hydrogel. Alginate was cross-linked to poly-L-lysine to define the pore size, and an additional outer layer of alginate was added to improve biocompatibility. Once produced, encapsulated cells were maintained in culture in the same conditions adopted for the free C2C12 myoblasts.
Mice
C57BL/6 control mice were purchased from Charles River Italia (Lecco, Italy). C57BL/6 IDUA knock-out (IDUA-ko) mouse, generated in the laboratory of E Neufeld, was kindly provided by JM Heard (Pasteur Institute, Paris, France). The IDUA-ko mouse model was created through gene disruption by insertion of the neomycin resistance gene into exon 6 of the murine IDUA sequence and represents a good model for patients with severe deficiency of IDUA activity. It is mainly characterized by undetectable plasma and tissue IDUA activity and elevated tissue glycosaminoglycan deposits. 15 All mice in the colony were genotyped by using multiplex PCR. A total of 12 IDUA-ko and 4 heterozygote mice were implanted with microcapsules. All animals were 12-weeks old. Following intra-peritoneal implantation mice were progressively sacrificed at 4, 8, 12 and 16 weeks after treatment.
Four 12-weeks-old, untreated IDUA-ko mice were sacrificed for the evaluation of basal tissue GAG levels and for histochemical analysis, while 6 age-matched wild-type animals were used as controls to evaluate plasma IDUA activity and histochemistry.
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Blood samples were obtained through retro-orbital bleeding. Urine samples were collected for 24 h in metabolic cages. Mice were sacrificed at four time points and blood and tissue samples were collected and analyzed.
All animal experimentation was performed in accordance to National and International Animal Ethic Guidelines.
Capsule implantation
Just before implantation encapsulated cells were analyzed for viability, and ability to produce and release IDUA by measuring enzyme activity in the culture medium.
Both IDUA-ko mice and heterozygote controls were anesthetized and then intra-peritoneally implanted with 4 ml of capsules resuspended in Hank's Balanced Salt Solution (Gibco-Invitrogen) containing an average of 8.6Â10 6 viable cells per mouse. Animals were monitored for a few hours after implantation. By the next day mice were normally active and the whole volume injected had been totally re-adsorbed.
IDUA enzyme assay
IDUA activity was evaluated by performing a fluorometric assay employing the substrate 4-methylumbelliferyl-a-L-iduronide (Glycosynth, Warrington, UK). Briefly, 10 mg of protein per sample were assayed by adding 20 ml of 2mM substrate + 20 ml of 0.1M Na-formiate buffer, pH 3.2 + 40 ml of 20mM D-saccaric acid 1.4-lattone. Incubation was performed at 37 1C for 17 h as reported in a previous paper. 27 The reaction was stopped by adding 1900 ml per sample of stop buffer (0.5 M NaHCO 3 /0.5 M Na 2 CO 3 pH 10.7); 4-methylumbelliferone (Sigma-Aldrich) was used as standard. Fluorescence was measured by using the Victor2 Multilabel Counter 1420 (Wallac-Perkin-Elmer, Milano, Italy), IDUA activity was given as nanomoles of substrate hydrolyzed in 17 h per mg of protein or ml of plasma (nmoles 17 h À1 mg À1 (ml)).
Cell samples were obtained as previously described. 28 Tissue samples were first homogenized in lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, pH 8.0, 0.1% Triton X-100) and, following centrifugation, the supernatants were recovered and protein concentration was determined. Blood samples were obtained either by retro-orbital bleeding or upon sacrifice of the animals. Blood was collected in heparinized tubes and plasma obtained through microcentrifugation at 3000 r.p.m. for 20 min, 10 ml of 5Â diluted plasma/sample was used to perform the enzyme assay, processed as described above. In each assay positive and negative controls were used.
Anti-IDUA antibodies determination
Anti-IDUA antibodies were determined by using an enzyme-linked immunosorbent assay: each well was coated with 50 ng of the recombinant IDUA (Aldurazyme (Laronidase) BioMarin) diluted in 100 ml of 0.1M NaHCO 3 , pH 9.6 and incubated for 2 h at 37 1C. Following on blocking at 4 1C and washing, three dilutions were assayed for each plasma sample, by incubating for 2 h at 37 1C. Anti-IDUA antibodies were detected by an anti-murine IgG secondary antibody conjugated with peroxidase (Sigma-Aldrich) diluted as suggested by the vendors. Detection was performed by TMB system (SigmaAldrich), absorbance was read in a Victor2 Multilabel Counter 1420 (WallacPerkin-Elmer) at 450 nm.
Tissue glycosaminoglycan content
Tissue GAG content was measured by using the Bjornsson's protocol, with modifications previously described. 29, 19 Briefly, tissues were lyophilized and then homogenized in 0.9% NaCl + 0.2% Triton X-100. The assay was performed by diluting 50 ml of blank (water), calibrators (chondroitin sulfate C) or samples with an equal volume of 8 M guanidine-HCl, and then 0.3% H 2 SO 4 / 0.75% Triton X-100. Samples were incubated on at 4 1C in the presence of alcian blue solution. Following centrifugation, pellets were washed with 40% DMSO/0.05% MgCl 2 and dissolved in 4 M guanidine-HCl/33% isopropanol/ 0.25% Triton X-100. All reagents were purchased at Sigma-Aldrich. Absorbance was measured at 620 nm. GAG content was calculated as mg per mg of proteins.
Tissue protein content
Tissue protein content was determined by using the Bio-Rad (Milano, Italy) protein assay following vendor's instructions. Standard curve was performed using different concentrations of bovine serum albumine (Sigma-Aldrich).
Urinary glycosaminoglycan content
Urinary GAG (expressed as mg of GAG per mg of creatinine) were determined as previously suggested with modification. 30, 31 For the assay, urine was diluted 1:10, 1:40 or 1:80 with water and then mixed with 220 ml of 1.9-dimethylmethylene blue chloride (8 M of 1,9-dimethylmethylene blue chloride (SigmaAldrich), 0.05 M of formiate (Sigma-Aldrich), 0.18 M Tris (Merck, Milano, Italy) pH 8.8). Absorbance was measured at 520 nm after 70 s. Reference solutions were prepared from chondroitin sulfate type C (Sigma-Aldrich). Urinary creatinine was measured by mixing 25 ml of diluted urine (1:5, 1:10) with 120 ml of a fivefold dilution of saturated picric acid (Sigma-Aldrich) and 120 ml of a 7.5 g l À1 solution of sodium hydroxide. After 20 min, absorbance at 535 nm was measured and compared with creatinine standard solutions (SigmaAldrich).
Histochemical analysis
Mice were sacrificed and tissues rapidly dissected and fixed for 48 h in Bouin's solution. Tissues were then washed in 70% ethanol, dehydrated and paraffin embedded. To visualize GAG deposits, 5 mm sections were obtained, de-paraffined and stained with 1% alcian blue solution, pH 1.0; 0.1% nuclear fast red was used as counterstain. All sections for the same organ obtained from control, untreated and treated IDUA-ko mice were stained at the same time.
Statistical analysis
Data in Figures 1-6 and 8 represent the average of different samples, the number of which is indicated under each figure. Bars represent s.e.m. or s.d. as reported in each figure. Statistical evaluation was performed by using Student's t-test. Differences were considered statistically significant at a value of Po0.05.
